other pocs , page-65

So S2 everything you posted only corroborated what I posted.

"We already knew Philips was installing a 2nd test cartridge production line. Also that they have now stated they are bringing the production wholly In-House. This IMO in part is to minimise the 3rd party supplier issues like those the Meritas POC has suffered (quality control) that eventually led to FDA trial suspension. This was a truly bad setback with FDA trial enrolments not programed to resume until early this year, with their final (revised) sumbission delayed until at least August. On the back of that news their overall POC sales only grew by 2.8% OUCH."

Now to take that further the 2.8% POC sales Growth was only boosted by the 43% growth in their diabetes POC "premier" (and HIV POC) which also accounted for the lions share of their 15.4% clinical lab sales revenue.
Without FDA Meritas is going nowhere in 2015. Tell you what how about you send them an email and ask them hiw sales are going, bet they won't respond, next you could ask is anyone in the sales team getting a Meritas sales bonus this xmass - pretty sure they won't respond to that also. Market leader - really in what matket?